Stocktoria
Alpha Teknova, Inc. TKNO
Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2021-06-25
Alpha Teknova, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $40.5M | $37.7M | $36.7M | $41.4M | $36.9M | $31.3M |
| Gross profit | $13.4M | $7.2M | $10.3M | $17.5M | $17.6M | $17.8M |
| R&D expense | $2.2M | $2.8M | $5.6M | $7.7M | $4.3M | $1.5M |
| Operating income | -$17.0M | -$26.1M | -$35.6M | -$49.7M | -$12.0M | $4.7M |
| Income tax | $58,000 | -$88,000 | -$298,000 | -$1.9M | -$2.8M | $1.2M |
| Net income | -$17.3M | -$26.7M | -$36.8M | -$47.5M | -$9.8M | $3.6M |
| EPS (diluted) | $-0.32 | $-0.57 | $-1.16 | $-1.69 | $-0.61 | $0.16 |
| Operating cash flow | -$8.6M | -$12.4M | -$18.8M | -$27.4M | -$9.1M | $2.5M |
| Free cash flow | -$9.8M | -$13.5M | -$26.7M | -$55.5M | -$28.9M | -$3.0M |
| Cash & equivalents | $5.9M | $3.7M | $28.5M | $42.2M | $87.5M | $3.3M |
| Inventory | $7.1M | $6.8M | $11.6M | $12.2M | $5.4M | $3.6M |
| Total assets | $103.6M | $118.8M | $128.6M | $152.3M | $166.5M | $62.9M |
| Total liabilities | $34.8M | $36.4M | $38.6M | $52.4M | $23.3M | $10.5M |
| Shareholders' equity | $68.8M | $82.4M | $90.0M | $99.9M | $143.2M | $16.8M |
Growth · year-over-year · Revenue CAGR 5.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +7.4% | +2.9% | -11.4% | +12.3% | +17.9% | — |
| Net income growth | — | — | — | — | -374.6% | — |
| EPS growth | — | — | — | — | -481.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.